C12N 2710/10322
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/10322 (New viral proteins or individual genes, new structural or functional aspects of) appears on 428 US grants and 531 published applications in this corpus.
Search patents in C12N- Granted patents
- 428
- Published applications
- 531
- Assignees
- 253
- Inventors
- 841
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 5 | 0 |
| 1997 | 5 | 0 |
| 1998 | 14 | 0 |
| 1999 | 16 | 0 |
| 2000 | 25 | 0 |
| 2001 | 17 | 6 |
| 2002 | 24 | 39 |
| 2003 | 25 | 52 |
| 2004 | 18 | 36 |
| 2005 | 14 | 26 |
| 2006 | 19 | 23 |
| 2007 | 16 | 18 |
| 2008 | 12 | 17 |
| 2009 | 14 | 21 |
| 2010 | 15 | 15 |
| 2011 | 7 | 15 |
| 2012 | 7 | 16 |
| 2013 | 7 | 13 |
| 2014 | 12 | 14 |
| 2015 | 18 | 17 |
| 2016 | 10 | 13 |
| 2017 | 14 | 17 |
| 2018 | 15 | 20 |
| 2019 | 10 | 20 |
| 2020 | 18 | 19 |
| 2021 | 11 | 20 |
| 2022 | 13 | 20 |
| 2023 | 13 | 20 |
| 2024 | 8 | 20 |
| 2025 | 14 | 20 |
| 2026 | 6 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis6 Oct 2026US 12,753,384 B2Cornell Research Foundation, Inc.
- Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer18 Aug 2026US 12,708,653 B2Endeavor Health Clinical Operations
- Engineered adenovirus vectors and uses thereof18 Aug 2026US 12,709,761 B2
- Oncolytic non-human adenoviruses and uses thereof30 Jun 2026US 12,668,612 B2Academisch Ziekenhuis Leiden (H.O.D.N. Lumc)
- Oncolytic tumor viruses and methods of use6 Jan 2026US 12,514,887 B2The Salk Institute for Biological Studies
- Compositions and methods for recombinant aav production24 Sep 2026US 2026/0286386 A1REGENXBIO Inc.
- Oncolytic non-human adenoviruses and uses thereof17 Sep 2026US 2026/0274898 A1Academisch Ziekenhuis Leiden (H.O.D.N. Lumc)
- Recombinant oncolytic adenovirus for cancer therapy20 Aug 2026US 2026/0240928 A1The Johns Hopkins University
- Engineered endothelial cells expressing an ets transcription factor6 Aug 2026US 2026/0226421 A1Angiocrine Bioscience, Inc.
- Helper gene control30 Jul 2026US 2026/0218230 A1Synplogen Co., Ltd.
Most cited
By later US patents
- Composition for introducing nucleic acid complexes into higher eucaryotic cells257US 5,547,932 ABoehringer Ingelheim International GmbH · 1996
- Eukaryotic layered vector initiation systems204US 5,814,482 A1998
- Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus184US 5,994,106 AGenVec, Inc. · 1999
- Alphavirus vector constructs167US 5,843,723 AChiron Corporation · 1998
- Targeting adenovirus with use of constrained peptide motifs158US 5,846,782 AGenVec, Inc. · 1998